S294: LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY

• M. Scully,
• J. de la Rubia,
• K. Pavenski,
• A. Metjian,
• P. Knöbl,
• F. Peyvandi,
• S. Cataland,
• P. Coppo,
• J. A. Kremer Hovinga,
• R. De Passos Sousa,
• F. Callewaert,
• S. Gunawardena,
• J. Lin

Affiliations

M. Scully

1 Department of Haematology, University College London Hospitals, London, United Kingdom

J. de la Rubia

2 Hematology Department, Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia

K. Pavenski

4 Departments of Medicine and Laboratory Medicine, St. Michael’s Hospital

A. Metjian

6 Division of Hematology, Department of Medicine, University of Colorado–Anschutz Medical Center, Denver, CO, United States of America

P. Knöbl

7 Department of Medicine

F. Peyvandi

1 Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria

S. Cataland

12 Department of Internal Medicine, Ohio State University, Columbus, OH, United States of America

P. Coppo

13 Department of Hematology, Reference Center for Thrombotic Microangiopathies (CNR-MAT), Saint-Antoine University Hospital, AP-HP, Paris, France

J. A. Kremer Hovinga

14 Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

R. De Passos Sousa

15 Sanofi, Lisbon, Portugal

F. Callewaert

16 Sanofi, Diegem, Belgium

S. Gunawardena

17 Sanofi, Cambridge, MA, United States of America

J. Lin

17 Sanofi, Cambridge, MA, United States of America